FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

UCB Gets Expanded Pediatric Indication for Briviact

[ Price : $8.95]

FDA approves a UCB expanded indication for Briviact (brivaracetam) tablets, oral solution, and injection to treat partial-onset se...

Anixa Gains IND Approval of CAR-T for Ovarian Cancer

[ Price : $8.95]

FDA approves an Anixa Biosciences IND for its CAR-T (Chimeric Antigen Receptor-T cell) therapy and its use in treating ovarian can...

Guide Revised on Trials Conducted During Covid

[ Price : $8.95]

FDA revises its guidance entitled Conduct of Clinical Trials of Medical Products During the Covid-19 Public Health Emergency.

De Novo Granted for Smart Knee Replacement

[ Price : $8.95]

FDA grants a de novo authorization to Zimmer Biomet and Canary Medical for their tibial extension for Persona IQ, the first smart ...

Lantern Pharma Gets Orphan Status LP-184

[ Price : $8.95]

FDA grants Lantern Pharma an orphan drug designation for LP-184 and its use in treating glioblastoma multiforme and other malignan...

EUA Withdrawn for Curative Covid Assay

[ Price : $8.95]

Federal Register notice: FDA announces that it has revoked the Emergency Use Authorization issued to Curative Inc. for its Curativ...

2 Guides on Device Performance Based Pathway

[ Price : $8.95]

Federal Register notice: FDA makes available two draft device-specific guidance documents for the Safety and Performance Based Pat...

Roche Drops Tecentriq Breast Cancer Indication

[ Price : $8.95]

Roche withdraws its accelerated approval for Tecentriq (atezolizumab) in combination with chemotherapy for treating adults with un...

Breckenridges Solifenacin Succinate ANDA Withdrawn

[ Price : $8.95]

Federal Register notice: FDA withdraws the approval of a Breckenridge Pharmaceutical ANDA for solifenacin succinate tablets (5mg a...

CDER Promotional eSubmission Validation Errors

[ Price : $8.95]

Federal Register notice: CDER announces that 10/18 is the effective date that it will begin rejecting submissions that fail either...